HYBRID EVENT: Join us in person in Singapore or attend virtually from anywhere.

3rd Edition of International Cancer & Immuno-Oncology Conference

March 15-17, 2027 | Singapore
March 15-17, 2027 | Singapore

Scientific Program 2026

Sergey Suchkov
Keynote Presentation (In-Person)
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM). Meanwhile, the era of genomics-based medicine and thus genomics biomarkers promises to provide molecular tests that will pe… » Read More

Patricia Tai
Keynote Presentation (In-Person)
Patricia Tai, University of Saskatchewan, Canada

Prostate cancer is a very common malignancy in men, particularly in the Western world, although its incidence is lower among Asians. It can be identified using the relatively new prostate-specific membrane antigen (PSMA) positron emission tomography (PET), a highly sensitive and … » Read More

Feng Yan
Oral Presentation (In-Person)
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China

Background Drug resistance, including Adriamycin-based therapeutic resistance, remains a challenge in breast cancer (BC) treatment. Studies have revealed that macrophages could play a pivotal role in mediating the chemoresistance of cancer cells. Accumulating evidence suggests th… » Read More

Chockalingam S
Oral Presentation (In-Person)
Chockalingam S, National Institute of Technology Warangal, India

Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase, has emerged as a critical driver of malignancy in diverse cancers such as anaplastic large cell lymphoma, non-small cell lung cancer, and neuroblastoma. Although ALK is normally activated by its ligands ALKAL1 and ALKA… » Read More

Mudalsha Ravina
Oral Presentation (In-Person)
Mudalsha Ravina, All India Institute of Medical Sciences, India

[18F]FDG PET/CT has become an integral component in the evaluation of Multiple Myeloma (MM), offering significant advantages in disease detection, staging, treatment response assessment, and prognostication. The Italian Myeloma criteria for PET Use (IMPeTUs) provide a standardize… » Read More

Patricia Tai
Oral Presentation (In-Person)
Patricia Tai, University of Saskatchewan, Canada

Aim: Degarelix, a GnRH antagonist for ADT, showed remarkable results in clinical trials. We launched Canada’s first off-site injection program to decentralize services from overloaded acute care settings. This is the first reported Canadian community experience with degarelix. Me… » Read More

Jiazhou Ye
Oral Presentation (In-Person)
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China

In this study we are the first worldwide to reveal a GP73-mediated regulatory network that promotes tumor angiogenesis and progression in Hepatocellular carcinoma (HCC) under hyperxia stress. Our findings demonstrated that GP73 plays crucial roles in tumor angiogenesis niche and … » Read More

Jinyan Feng
Oral Presentation (In-Person)
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China

Chemoresistance remains the predominant cause of treatment failure in osteosarcoma (OS), yet its underlying molecular circuitry remains poorly defined. To address this gap, we conducted a series of mechanistic and clinically informed studies integrating molecular biology, epitran… » Read More

Yanyu Qi
Oral Presentation (In-Person)
Yanyu Qi, Chengdu Third People's Hospital, China

Objective: To compare the short-term therapeutic efficacy and safety of bevacizumab versus anlotinib, each in combination with chemotherapy, for the treatment of advanced lung adenocarcinoma with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (… » Read More

Sergey Suchkov
Oral Presentation (In-Person)
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation

Individualizing patient treatment is a core objective of the medical field. Meanwhile, the inherent variability of cancer illustrating the molecular differences between tumors, securing the linkages of those differences to an effective drug and resulting in immense patient benefi… » Read More

Jinzhao Song
Oral Presentation (In-Person)
Jinzhao Song, Hangzhou Institute of Medicine, Chinese Academy of Sciences, China

Minimal residual disease (MRD) can persist in cancer patients even after potential cure, resulting in cancer recurrence and contributing to the low five-year survival rate of cancer patients. Currently, circulating tumor DNA (ctDNA) is the preferred biomarker for MRD detection. H… » Read More

Maria S Shmelkova
Oral Presentation (In-Person)
Maria S Shmelkova, Burdenko National Research Neurosurgery Center, Russian Federation

Primary intraocular lymphomas (PIOL) or vitreoretinal lymphomas (VRL) are a type of primary central nervous system lymphoma (PCNSL), accounting for approximately 2–3% of all non-Hodgkin lymphomas and developing in about 11–25% of patients with PCNSL. Morphologically, PIOLs are di… » Read More

Han Sun
Oral Presentation (In-Person)
Han Sun, Liaoning Cancer Hospital & Institute, China

Background: Radiotherapy (RT) can induce immunogenic cell death and enhance tumor antigen release and presentation, thereby augmenting the host anti-tumor immune response. The combination of PD-1 inhibitor tislelizumab with RT may produce synergistic effects and improve outcomes … » Read More

Yuanhao Su
Oral Presentation (In-Person)
Yuanhao Su, Second Affiliated Hospital of Xi'an Jiaotong University, China

Background: The global incidence of papillary thyroid cancer (PTC) has been increasing in recent years, placing greater demands on healthcare systems worldwide. While standard treatments such as surgery combined with radioactive iodine therapy and chemoradiotherapy are common, ma… » Read More

Yongke Wu
Oral Presentation (In-Person)
Yongke Wu, The Second Affiliated Hospital of Xi’an Jiaotong University, China

Background: Elderly patients with papillary thyroid carcinoma (PTC) constitute a unique subgroup in clinical practice, often exhibiting more aggressive tumor characteristics. Although current guidelines offer few specific recommendations for patients aged ≥55 years, it is vita… » Read More

Yanni Zhang
Oral Presentation (In-Person)
Yanni Zhang, Liaoning Cancer Hospital & Institute, China

Background: Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), remains a leading cause of cancer-related mortality worldwide. This study investigates the impact of different treatment modalities, namely concurrent chemoradiotherapy (CCRT), chemoimmunothera… » Read More

Li Ma
Oral Presentation (In-Person)
Li Ma, Beijing Chest Hospital, China

Background: Accurate diagnosis of malignant pleural effusion (MPE) using biomarkers remains challenging. C-C motif chemokine ligand 2 (CCL2), a chemokine markedly overexpressed under pathological conditions, has emerged as a pivotal biomarker across various diseases and plays a k… » Read More

Hoang Minh Quan Pham
Oral Presentation (In-Person)
Hoang Minh Quan Pham, Taipei Medical University, Taiwan

Background: Biomarkers associated with response to immune checkpoint blockade (ICB) in lung adenocarcinoma (LUAD) remain incompletely defined. This study examined the transcriptional landscape of BCL2A1 in CD8? T cells and evaluated its association with clinical outcomes in ICB-t… » Read More

Megadeepan Senthilkumar
Oral Presentation (In-Person)
Megadeepan Senthilkumar, Kidwai Memorial Institute of Oncology, India

Background: Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome with heterogeneous triggers, ranging from genetic predispositions and immunodeficiencies to malignancies and infections. We report four paediatric cases highlighting the clinical spectrum, diagno… » Read More

He Haowei
Poster Presentation (In-Person)
He Haowei, Jinling Hospital, China

Background: Metastatic renal cell carcinoma (mRCC) remains a therapeutic challenge with poor prognosis, as current immunotherapy combinations often encounter resistance. Immune escape is a key driver of spontaneous metastasis; however, the underlying regulatory mechanisms in mRCC… » Read More

Li Su
Poster Presentation (In-Person)
Li Su, Harvard T.H. Chan School of Public Health, United States

Rationale: Metabolic reprogramming is a hallmark of lung cancer and a source of druggable vulnerabilities. Bridging mechanistic metabolic signatures with clinical prognostication may reveal targetable pathways that inform precision therapy and biomarker guided trials. However, th… » Read More

Xiaoming Yi
Poster Presentation (In-Person)
Xiaoming Yi, Jinling Hospital, China

Background: Renal cell carcinoma (RCC) is a common malignant tumor of the urinary system, with clear cell RCC (ccRCC) representing its predominant subtype. The pathogenesis of ccRCC remains incompletely understood. KCNN4 (potassium calcium-activated channel subfamily N member 4) … » Read More

Xingyue Chen
Poster Presentation (In-Person)
Xingyue Chen, Southeast University, China

My presentation addresses one of the most pressing challenges in oncology: Treatment Resistance. I will focus on a novel strategy to overcome oxaliplatin resistance in colorectal cancer, titled " Phytohormone strigolactams overcomes oxaliplatin-resistance in colorectal cancer by … » Read More

Yutong Zhou
Poster Presentation (In-Person)
Yutong Zhou, Southeast University, China

The emergence of treatment resistance remains a central challenge in oncology, often stemming from the limited chemical diversity and predictable mechanisms of existing drugs. We present a transformative chemical strategy to combat this by creating novel nucleoside-boron hybrids … » Read More

Fu Dian
Poster Presentation (In-Person)
Fu Dian, Jinling Hospital, China

Background: Urothelial carcinoma is frequently managed with chemotherapy combined with immunotherapy or antibody-drug conjugates (ADCs) targeting HER2 and Nectin4, which have shown promising efficacy in clinical practice. However, treatment response often diminishes over time, po… » Read More

YouTube
WhatsAppWhatsApp